Invention Grant
- Patent Title: Antisense oligonucleotides optimized for kidney targeting
- Patent Title (中): 针对肾靶向优化的反义寡核苷酸
-
Application No.: US10946498Application Date: 2004-09-21
-
Publication No.: US08258105B2Publication Date: 2012-09-04
- Inventor: Andrew M. Siwkowski , Edward Wancewicz , Thomas A. Leedom , Lynnetta Watts , Mausumee Guha , Brett P. Monia
- Applicant: Andrew M. Siwkowski , Edward Wancewicz , Thomas A. Leedom , Lynnetta Watts , Mausumee Guha , Brett P. Monia
- Applicant Address: US CA Carlsbad
- Assignee: Isis Pharmaceuticals, Inc.
- Current Assignee: Isis Pharmaceuticals, Inc.
- Current Assignee Address: US CA Carlsbad
- Agency: Jones Day
- Main IPC: C12N15/11
- IPC: C12N15/11
Abstract:
The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
Public/Granted literature
- US20050113326A1 Antisense oligonucleotides optimized for kidney targeting Public/Granted day:2005-05-26
Information query
IPC分类:
